@article {RussellFa19, author = {RT Russell and J Topping and CR Kingsland}, title = {Should Down{\textquoteright}s syndrome risk and screening information be discussed as part of IVF treatment?}, volume = {95}, number = {Suppl 1}, pages = {Fa19--Fa19}, year = {2010}, doi = {10.1136/adc.2010.189746.26}, publisher = {BMJ Publishing Group}, abstract = {To assess the current appetite and provision of information regarding Down{\textquoteright}s syndrome as part of the infertility pathway, the authors conducted a survey of both patients, in vitro fertilization (IVF) clinics and obstetricians in the UK. 18\% of IVF units routinely provided patients with information about Down{\textquoteright}s Syndrome, while 38\% of clinics had a selective policy based on patient demographics. 44\% of clinics did not provide information. However, 78\% of clinics surveyed believed the provision of this information was appropriate and should be discussed prior to treatment commencing. In a survey of 50 obstetricians and feto-maternal specialists, 89\% responded in favour of patients being given information about their individualised risk of Down{\textquoteright}s Syndrome with 83\% suggesting it is the responsibility of the IVF units to do this. 75\% of respondents suggested that information regarding available screening tests should also be discussed as part of the consultation. All patients the authors surveyed welcomed a policy of providing information about their individual risk of Down{\textquoteright}s Syndrome, and the available screening options. 98\% of patients were aware of Down{\textquoteright}s Syndrome, with 54\% of patients aware that incidence increased with maternal age. 80\% of patients identified {\textquoteleft}amniocentesis{\textquoteright} as the only test available, while 14\% of patients were aware of the availability of Combined testing and or nuchal translucency. The majority of patients would consider an appropriate test when given the option, with 98\% agreeing that combined screening would be their preferred test. 10\% of patients would reconsider IVF treatment if their age related risk was considered high.}, issn = {1359-2998}, URL = {https://fn.bmj.com/content/95/Suppl_1/Fa19.1}, eprint = {https://fn.bmj.com/content}, journal = {Archives of Disease in Childhood - Fetal and Neonatal Edition} }